Masatoshi Eto

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma

Yoshihiro Komohara, Hasita Horlad, Koji Ohnishi et al. · Cancer Science · 2011 · 266 citations

Medicine, Cell Biology, Oncology +17

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

Marine Gross‐Goupil, Tae‐Geon Kwon, Masatoshi Eto et al. · Annals of Oncology · 2018 · 257 citations · Full text

Medicine, Oncology, Pharmacology +17

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer et al. · The Lancet Oncology · 2023 · 163 citations · Full text

Medicine, Oncology, Pharmacology +10